$CNTB

Biotech stocks rose on company-specific catalysts. Virax Biolabs (VRAX) jumped over 100% after signing an exclusive multi-country supply agreement with Fosun Diagnostics for ImmuneSelect. Forte Biosciences (FBRX) gained about 78% on positive Phase 1b vitiligo data for FB102. First Tracks (TRAX) rose ~56% without news. TransCode (RNAZ) and Connect Biopharma (CNTB) also climbed; Sanuwave (SNWV) fell guidance and expects Q2 revenue of $8.5m to $9.5m.

Connect Biopharma (Nasdaq: CNTB) said it has completed enrollment in its Phase 2 Seabreeze STAT Asthma study of rademikibart (adjunct to standard of care) for acute asthma exacerbations in patients with type 2 inflammation; it enrolled 160 participants. The company expects topline data in early September 2026, plans to complete COPD enrollment this month, and aims to align on a Phase 3 program with the FDA later this year.

Huang James purchased 150,000 indirectly-held shares of Connect Biopharma Holdings Ltd (CNTB) at $2.48 ($0.37M total) on 2026-05-29.

Connect Biopharma Holdings Ltd director James Huang has filed an initial Form 3, indicating an indirect beneficial ownership of 12,000,000 Ordinary Shares through Panacea Venture Healthcare Fund II, L.P. While Huang may be deemed to share beneficial ownership due to his ownership chain with entities related to the fund, he explicitly disclaims such beneficial ownership, clarifying that the holding is at the fund level. This filing provides transparency regarding significant shareholdings linked to company leadership.

RedChip Companies will broadcast interviews with Connect Biopharma Holdings Limited (Nasdaq:CNTB) and Bimergen Energy Corp. (OCTQB:BESS) on its "RedChip Small Stocks, Big Money™" program on Bloomberg TV. The show will air this Saturday, November 15, at 7 p.m. ET. Interviews will feature the CEOs discussing advancements in treating severe respiratory diseases and expanding portfolios of utility-scale battery energy storage systems, respectively.

SAN DIEGO, Nov. 24, 2025 ( GLOBE NEWSWIRE ) -- Connect Biopharma Holdings Limited ( Nasdaq: CNTB ) ( "Connect Biopharma", "Connect", or the "Company" ) , a clinical-stage biopharmaceutical company focused on transforming care for the treatment of inflammatory diseases, today announced that ...

SAN DIEGO, Nov. 24, 2025 ( GLOBE NEWSWIRE ) -- Connect Biopharma Holdings Limited ( NASDAQ:CNTB ) ( "Connect Biopharma", "Connect", or the "Company" ) , a clinical-stage biopharmaceutical company focused on transforming care for the treatment of inflammatory diseases, today announced that ... ET.

Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades, downgrades and initiations, please see our analyst ratings page.

SAN DIEGO, Aug. 27, 2025 ( GLOBE NEWSWIRE ) -- Connect Biopharma Holdings Limited ( Nasdaq: CNTB ) ( Connect Biopharma, Connect or the Company ) , a clinical-stage biopharmaceutical company focused on transforming care for the treatment of inflammatory diseases, today announced that Company ...

- Initiated Phase 2 Seabreeze STAT asthma and COPD studies evaluating rademikibart as an adjunct treatment for acute exacerbations ...